导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.58% | 2063/4773 |
| 近一周 | -2.14% | 1313/5462 |
| 近一月 | -3.59% | 1846/5421 |
| 近一季 | -1.94% | 1106/5209 |
| 近半年 | 0.02% | 1207/4920 |
| 近一年 | 4.16% | 1780/4366 |
| 近两年 | 49.17% | 1490/2954 |
| 近三年 | 32.37% | 955/2253 |
| 成立以来 | 95.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.12% 3528/4961 |
8.46% 2591/5312 |
- - |
- - |
| 2025 | 19.02% 2261/4813 |
-0.41% 2234/3635 |
3.22% 1103/4076 |
14.70% 2880/4524 |
0.93% 1652/4813 |
| 2024 | 19.14% 550/3463 |
4.71% 437/2808 |
-2.22% 1158/3014 |
16.47% 1445/3129 |
-0.08% 1311/3463 |
| 2023 | -8.30% 997/2656 |
4.80% 866/2280 |
-4.33% 1139/2385 |
-1.78% 580/2515 |
-6.88% 1957/2655 |
| 2022 | -19.52% 861/2207 |
-12.74% 652/1919 |
6.99% 554/2016 |
-14.30% 1066/2113 |
0.59% 1481/2208 |
| 2021 | -1.29% 793/1822 |
-1.48% 498/1255 |
6.12% 766/1330 |
-6.02% 891/1466 |
0.47% 1105/1822 |
| 2020 | 41.69% 285/1250 |
-7.41% 542/1028 |
17.01% 396/1067 |
14.74% 259/1164 |
13.97% 316/1184 |
| 2019 | 42.76% 205/1092 |
25.21% 474/754 |
0.89% 151/804 |
4.64% 188/850 |
7.99% 367/918 |
| 2018 | -21.75% 219/834 |
- - |
- - |
- - |
-12.27% 430/691 |
| 2017 | 24.63% 122/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.68% 163/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 创金合信沪深300指数增强A VS. 长安沪深300非周期A(740101) |